AIMS: Cyclo-oxygenases 1 and 2 (COX-1 and COX-2) are key enzymes in prostaglandin biosynthesis. COX-2 is induced by a wide variety of stimuli, and present during inflammation. COX-2 overexpression has been observed in colon, head and neck, lung, prostate, stomach, and breast cancer. In colon and gastric cancer, COX-2 expression was associated with angiogenesis. The aim of this study was to determine the relation between COX-2 expression and angiogenesis in breast cancer, and to correlate the expression of this enzyme with classic clinicopathological parameters. METHODS: COX-2 expression was investigated by immunohistochemistry and western blotting analysis. The expression of COX-2 was then related to age, histological grade, nodal status, oestrogen receptor status, p53 expression,c-erb-B2 overexpression, mitotic counts, MIB-1 labelling index, apoptotic index, sialyl-Tn expression, transforming growth factor alpha expression, microvessel density, and disease free survival in 46 patients with invasive ductal breast carcinoma. RESULTS: By means of immunohistochemistry, COX-2 expression was detected in eight of the 46 carcinomas studied. Western blotting showed COX-2 protein expression in the same breast tumours, but not in normal adjacent tissues. The density of microvessels immunostained with anti-F-VIII related antigen was significantly higher in patients with COX-2 expression than in those without expression (p = 0.03). In addition, COX-2 was significantly associated with the presence of sialyl-Tn expression (p = 0.02), lymph node metastasis (p = 0.03), a high apoptotic index (p = 0.03), and a short disease free survival (p = 0.03) in univariate analyses. CONCLUSIONS: These data suggest that COX-2 expression is associated with angiogenesis, lymph node metastasis, and apoptosis in human breast cancer. Moreover, these results warrant further studies with larger series of patients to confirm the association with short disease free survival in patients with breast cancer.
AIMS: Cyclo-oxygenases 1 and 2 (COX-1 and COX-2) are key enzymes in prostaglandin biosynthesis. COX-2 is induced by a wide variety of stimuli, and present during inflammation. COX-2 overexpression has been observed in colon, head and neck, lung, prostate, stomach, and breast cancer. In colon and gastric cancer, COX-2 expression was associated with angiogenesis. The aim of this study was to determine the relation between COX-2 expression and angiogenesis in breast cancer, and to correlate the expression of this enzyme with classic clinicopathological parameters. METHODS:COX-2 expression was investigated by immunohistochemistry and western blotting analysis. The expression of COX-2 was then related to age, histological grade, nodal status, oestrogen receptor status, p53 expression,c-erb-B2 overexpression, mitotic counts, MIB-1 labelling index, apoptotic index, sialyl-Tn expression, transforming growth factor alpha expression, microvessel density, and disease free survival in 46 patients with invasive ductal breast carcinoma. RESULTS: By means of immunohistochemistry, COX-2 expression was detected in eight of the 46 carcinomas studied. Western blotting showed COX-2 protein expression in the same breast tumours, but not in normal adjacent tissues. The density of microvessels immunostained with anti-F-VIII related antigen was significantly higher in patients with COX-2 expression than in those without expression (p = 0.03). In addition, COX-2 was significantly associated with the presence of sialyl-Tn expression (p = 0.02), lymph node metastasis (p = 0.03), a high apoptotic index (p = 0.03), and a short disease free survival (p = 0.03) in univariate analyses. CONCLUSIONS: These data suggest that COX-2 expression is associated with angiogenesis, lymph node metastasis, and apoptosis in humanbreast cancer. Moreover, these results warrant further studies with larger series of patients to confirm the association with short disease free survival in patients with breast cancer.
Authors: T Hida; Y Yatabe; H Achiwa; H Muramatsu; K Kozaki; S Nakamura; M Ogawa; T Mitsudomi; T Sugiura; T Takahashi Journal: Cancer Res Date: 1998-09-01 Impact factor: 12.701
Authors: L J Hixson; D S Alberts; M Krutzsch; J Einsphar; K Brendel; P H Gross; N S Paranka; M Baier; S Emerson; R Pamukcu Journal: Cancer Epidemiol Biomarkers Prev Date: 1994 Jul-Aug Impact factor: 4.254
Authors: Henriqueta Coimbra Silva; Vera Alves; Luis Alcides Mesquita Nogueira; Manuel Santos Rosa; Lina Carvalho; Fernando Regateiro Journal: Med Oncol Date: 2011-06-03 Impact factor: 3.064
Authors: Fredika M Robertson; Ann-Marie Simeone; Anthony Lucci; John S McMurray; Sukhen Ghosh; Massimo Cristofanilli Journal: Cancer Date: 2010-06-01 Impact factor: 6.860
Authors: Nagehan Ozdemir Barısık; Sevinc Hallac Keser; Aylin Ege Gul; Sibel Sensu; Nilufer Onak Kandemir; Hasan Fehmi Kucuk; Mahmut Gumus; Nimet Karadayı Journal: Med Oncol Date: 2010-03-31 Impact factor: 3.064
Authors: Michelle D Holmes; Wendy Y Chen; Stuart J Schnitt; Laura Collins; Graham A Colditz; Susan E Hankinson; Rulla M Tamimi Journal: Breast Cancer Res Treat Date: 2011-07-05 Impact factor: 4.872
Authors: Julie M Wu; Mary Jo Fackler; Marc K Halushka; Diana W Molavi; M Evangeline Taylor; Wei Wen Teo; Constance Griffin; John Fetting; Nancy E Davidson; Angelo M De Marzo; Jessica L Hicks; Dhananjay Chitale; Marc Ladanyi; Saraswati Sukumar; Pedram Argani Journal: Clin Cancer Res Date: 2008-04-01 Impact factor: 12.531